Pioneering microbiome research internationally

The intestine is at the centre of medical-scientific interest – or more precisely, the trillions of bacteria that colonise it. With increasing research into the microbiome, it is becoming clearer as to which central role intestinal bacteria play for our health or for the development – and the treatment – of diseases. Through its scientific work, Institut AllergoSan has been decisively shaping the medicine of the 21st century for over 30 years, and ongoing research is being conducted on bacteria that naturally occur in the human body!

Home - About Us - Research & Development - International Research

Contents

Institut AllergoSan - Shaping the future of probiotic medicine

Numerous clinical studies clearly prove the therapeutic success of these probiotic bacteria in very different clinical pictures, from antibiotic-associated diarrhoea to depression and recurrent bacterial vaginosis.

Quality is our DNA

Institut AllergoSan has been inextricably linked with the topics of probiotic research for around 30 years and the OMNi-BiOTiC® brand is number 11 on the probiotics market. Anita Frauwallner, founder and director of Institut AllergoSan: “Research and high-quality studies are the cornerstone of our probiotics. We specifically select strains of bacteria that occur in a healthy human body and thus have the best possible conditions to settle and multiply in our intestines. And we also show this in clinical studies conducted by renowned clinics.”

The stringent procedure for selecting such human-derived bacteria is particularly well illustrated in a study2 conducted by Vienna General Hospital: Exactly those bacteria responsible for healthy vaginal colonisation were isolated from the intestines and vaginas of healthy women. The strongest of these are selected in lengthy research processes in order to treat women with diseases such as recurrent urinary tract infections, bacterial vaginosis or fungal infections in a completely natural way – and in a causal and sustainable way – with probiotic bacteria that live permanently in healthy people. “Institut AllergoSan spends all the knowledge it has acquired over decades and large sums of money on research to identify exactly those strains of bacteria for various health problems that are then used in products under the name OMNi-BiOTiC® and whose noticeable effect turns customers into enthusiastic fans,” Anita Frauwallner describes.

Doctors and pharmacists trust these probiotics because there is proof of their effectiveness, which is published in high-ranking scientific journals. For example, the study on the probiotic treatment of antibiotic-associated diarrhoea, which was published in the internationally renowned American Journal of Gastroenterology, was selected by the WGO at the time as one of the 15 best probiotics studies worldwide. High recognition was also given to the study on the use of probiotics during pregnancy, which make it possible to modulate the immune system and thus significantly reduce the occurrence of allergies, asthma and neurodermatitis even in genetically predisposed children. These results were published in the leading scientific journal Allergy as the PANDA study. A special study success was published in the journal Alimentary Pharmacology and Therapeutics: Together with the Medical University of Graz, it was clearly shown that a specially developed probiotic could improve disturbed liver function even in patients with severe liver cirrhosis – before then an option unheard of that, moreover, does not entail any undesirable side effects, as would be the case with a liver transplant – the only alternative to this probiotic treatment.

Ongoing investments in research

Recent research successes include a study on the successful use of a specifically formulated probiotic to reduce adverse effects after colonoscopy3. A colonoscopy is considered the most important medical examination for the prevention and early detection of colorectal cancer, and the success of this examination depends largely on adequate bowel emptying. However, the lavage solution administered not only flushes out faecal residues but also good intestinal bacteria. In this study with 91 subjects, we were able to prove that taking these selected probiotic bacterial strains for only four weeks directly after the colonoscopy prevents a miscolonisation of pathogenic germs during this vulnerable period and positively influences the intestinal microbiome. It should also be emphasised that significantly fewer days with constipation occurred when taking the probiotic and, in addition, fewer days with gastrointestinal complaints such as diarrhoea or flatulence were recorded in the probiotic group. These research data offer extremely great potential to increase the general acceptance of this important check-up and achieve a reduction in the risk of colorectal cancer.

Research around Coronavirus is also showing impressive results. In the wake of the Corona crisis, people in health and social care professions in particular were faced with major challenges. They were not only exposed to a higher risk of infection but also to strong psychological stress. The stress load manifests itself in symptoms such as depression, insomnia and anxiety. Chronic stress has been scientifically proven to lead to a change in the intestinal microbiome; specifically, the intestinal mucosa is also severely affected. As part of a situation analysis, the effect of probiotics on psychological stress parameters was investigated in around 14,000 participants from health professions during the COVID-19 pandemic in Germany4. The results of this situation analysis impressively show that a probiotic with B vitamins that specifically acts on the gut-brain axis was able to improve mental and physical well-being during high stress levels. Within just two weeks, the use of medically relevant probiotics can improve stress-related complaints such as fatigue and mental exhaustion. We are currently planning a placebo-controlled study to confirm these sensational results.

Two studies on the successful use of a specific pathogen-inhibiting probiotic for antibiotic-induced diarrhoea show particularly exciting results. On the one hand, we were able to prove in a study with over 200 patients that significantly fewer side effects of antibiotic treatment occurred in the probiotic group and, in addition, not a single Clostridium difficile infection was observed – a germ that can cause life-threatening dysbiosis in the intestine. Particularly remarkable was the fact that not a single case of diarrhoea occurred in the high-risk group of patients over 90 years of age, whereas 45% of the patients in the control group who did not receive probiotics had diarrhoea. These positive effects on the patient are of course also noticeable in the hospital’s operations: By reducing diarrhoea, hygiene measures and personnel costs can be reduced5. Excellent results were shown in another study in which the probiotic was administered to cancer patients undergoing chemotherapy and simultaneous antibiotic therapy: not a single patient developed diarrhoea despite the combination of chemotherapy with many side effects plus antibiotics. This not only helps patients to have a better quality of life but also leads to a more optimal course of therapy and fewer discontinuations of chemotherapy6.

It is these studies and currently more than 40 other ongoing projects that make Institut AllergoSan the Austrian centre of microbiome research: “The future belongs to probiotic medicine. We are proud to be able to make a decisive contribution to this with our research and product development,” Anita Frauwallner summarises.

1 IMS PharmaTrend® monatlich; individuelle Marktbasis aus OTC 3 — 03F1 Probiotische Produkte für den Verdauungstrakt und ausgewählten Wettbewerbern; MAT 07/2017; Umsatz

2 Domig, K. J. et al. Strategies for the evaluation and selection of potential vaginal probiotics from human sources: an exemplary study. Benef. Microbes 5, 263–272 (2014)

3 Labenz, J. et al. “Application of a multi-species probiotic reduces gastro-intestinal discomfort and induces microbial changes after a colonoscopy.” Frontiers in Oncology (2022).

4 Frauwallner A. „Der positive Effekt eines Multispezies-Probiotikums auf Stressresilienz und Schlafqualität“ OM & Ernährung, vol. 179, pp F40-F46 (2022)

5 Gänzer et al. „Einsatz von Probiotika bei Antibiose-Prävention einer antibiotikaassoziierten Diarrhoe bei älteren Patienten“ Wiener klinisches Magazin, vol. 25, pp 12-19 (2022).

6 Rabl et al. „Der positive Effekt eines Multispezies-Probiotikums bei chirurgischen Patienten mit Antibiose.” Chirurg. Allg. Kompakt, vol. 10, pp. 475-478 (2021).

Research investments

Institut AllergoSan continuously invests in research and product development. As a result, it offers its customers natural substances whose effect is not only quickly noticeable for the user, but also proven by scientific studies.

Research Projects

Here is a selection of PubMed published studies on various indications in which OMNi-BiOTiC® was used and scientifically tested:
  • Medizinische Universität Graz – Prof. C. Castellani – Inhibiting pathogens
    Kienesberger et al. „Insights into the Composition of a Co-Culture of 10 Probiotic Strains (OMNi BiOTiC® AAD10) and Effects of Its Postbiotic
    Culture Supernatant.“ Nutrients, vol. 14, pp. 1194 (2022)
  • Diakonie Klinikum Jung Stilling Siegen – Prof. Joachim Labenz – Colonoscopy
    Labenz, J. et al. „Application of a multispecies probiotic reduces gastro-intestinal discomfort and induces microbial changes after colonoscopy.“
    Frontiers in Oncology (2022).
  • University of North Texas – Danielle T. Phillippi – Environmental toxins
    Phillippi, D.T. et al. „Inhaled diesel exhaust particles result in microbiome-related systemic inflammation and altered cardiovascular disease
    biomarkers in C57Bl/6 male mice.“ Particle and Fibre Toxicology; vol. 19(1):10 (2022).
  • Medizinische Universität Graz – Prof. E. Z. Reininghaus – Depression
    K. Kreuzer et al., „ The PROVIT Study-Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder-A Randomized, Placebo-Controlled Trial.” Metabolites, vol 12 (8), pp 770 (2022).
  • Institut Allergosan – Mag. A. Frauwallner – Stress Rest Marktanalyse Deutschland
    Frauwallner A. „Der positive Effekt eines Multispezies-Probiotikums auf Stressresilienz und Schlafqualität“ OM & Ernährung, vol. 179, pp F40-F46 (2022).
  • Bezirkskrankenhaus Schwaz – Prim. Prof. H. Gänzer – Internal medicine patients with antibiotics
    Gänzer et al. „Einsatz von Probiotika bei Antibiose-Prävention einer antibiotikaassoziierten Diarrhoe bei älteren Patienten“ Wiener klinisches Magazin, vol. 25, pp 12-19 (2022).
  • University of North Texas – Sarah Daniel – Environmental pollution
    Daniel, S. et al. „Exposure to diesel exhaust particles results in altered lung microbial profiles, associated with increased reactive oxygen species/reactive nitrogen species and inflammation, in C57Bl/6 wildtype mice on a high-fat diet.“ Particle and Fibre Toxicology; vol. 18(1):3 (2021).
  • LKH Leoben – Prim. Prof. H. Rabl – Patients post-surgery with antibiotics
    Rabl et al. ”Der positive Effekt eines Multispezies-Probiotikums bei chirurgischen Patienten mit Antibiose.” Chirurg. Allg. Kompakt, vol. 10, pp. 475-478 (2021).
  • Velleja Forschungsinstitut Mailand – Dr. F. Di Pierro – COVID-19
    Di Pierro et al. “The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection.” Minerva Medica, vol. 112, pp. 514-516 (2021).
  • Wuhan University of Science and Technology – Dr. Q. Wang – COVID-19
    Wang et al. “Oropharyngeal Probiotic ENT-K12 Prevents Respiratory Tract Infections Among Frontline Medical Staff Fighting Against COVID-19: A Pilot Study.” Front. Bioeng. Biotechnol., vol. 9, pp. 646184 (2021).
  • Kinderwunsch Institut Schenk – Dr. M. Schenk – In-vitro-Fertilisation
    M. Schenk et al., “Effect of probiotics on vaginal Ureaplasma parvum in women suffering from unexplained infertility”, ReProd BioMed Online, (2021)
  • Medizinische Universität Graz – Prof. V. Stadlbauer-Köllner – Hepatology
    V. Stadlbauer-Köllner, „Probiotika zur Verbesserung der Leberfunktion bei Leberzirrhose“, OM u Ernährung, vol. 173, pp. 54-61 (2020).
  • Medizinische Universität Graz – Prof. E. Z. Reininghaus – Depression
    E. Z. Reininghaus et al., “PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial,” Nutrients, vol. 12, pp. 3422, (2020)
  • Medizinische Universität Graz – Prof. M. Stradner – Psoriasis-Arthritis
    A. Haidmayer, et al. “Effects of Probiotic Strains on Disease Activity and Enteric Permeability in Psoriatic Arthritis–A Pilot Open-Label Study.” Nutrients, vol. 12, pp. 2337 (2020)
  • Mid Sweden University – Dr. M. Jong – AAD in nursing homes
    H. A. Van Wietmarschen et al. “Probiotics use for antibiotic-associated diarrhea: A pragmatic participatory evaluation in nursing ho- mes,” BMC Gastroenterol., vol. 20, pp. 151 (2020)
  • Medizinische Universität Graz – Prof. E. Z. Reininghaus – Depression
    A. Reiter et al., “Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder—Preliminary Results of the PROVIT Study,” Nutrients, vol. 12, pp. 2575, (2020)
  • Medizinische Universität Graz – Prof. R. Krause – Multiresistent Bacteria
    I. Zollner-Schwetz et al. “Effect of a multispecies probiotic on intestinal and skin colonization by multidrug-resistant gram-negative bacteria in patients in a long-term care facility: A pilot study,” Nutrients, vol. 12, pp. 1586 (2020)
  • Review – Dr. V. Stiegelbauer – Probiotics quality
    L. Grumet, et al. “The Development of High-Quality Multispecies Probiotic Formulations: From Bench to Market,” Nutrients, vol. 12, pp. 2453 (2020). Qualitätskriterie
  • Medizinische Universität Graz – Prof. V. Stadlbauer-Köllner – Hepatology
    A. Horvath et al. “Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis,” Nutri- ents, vol. 12, pp. 1874 (2020)
  • Medizinische Universität Graz – Prof. V. Stadlbauer-Köllner – Type 2 Diabetes
    Horvath et al. “Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study.” Eur. J. Nutr., (2019).
  • Universität Graz – Prof. B. Schütz – Absorbtion of substances in the postmenopause
    Stiegelbauer et al. “Der Effekt eines Multispezies-Probiotikums auf die Mikronährstoffaufnahme, Hormonproduktion und Entzün- dungsreaktionen bei postmenopausalen Frauen ”, OM u Ernährung, vol. 168, pp. 63-67 (2019).
  • Medizinische Universität Graz – Prof. P. Holzer – Antibiotics and Microbiome
    Jačan et al. “Synergistic and antagonistic interactions between antibiotics and synbiotics is modifying the murine fecal microbiome,” Eur. J. Nutr., pp. 1-14 (2019).
  • Europa Universität Viadrina Frankfurt – Dr. D. Lazik – Performance enhancement in sport
    Lazik et al. “Der Effekt von Multispezies-Probiotika auf die intestinale Barrierefunktion, Entzündungsreaktionen und Leistungsfähig- keit bei Athleten – Eine retrospektive Studie bei Leistungssportlern einer Football Bundesliga-Mannschaft”, OM u Ernährung, vol.
    167, pp. 27- 34 (2019).
  • Medizinische Universität Graz – Prof. V. Stadlbauer-Köllner – Sepsis and the Microbiome
    Stadlbauer et al. “Dysbiosis in early sepsis can be modulated by a multispecies probiotic: a randomised controlled pilot trial,” Benef. Microbes, vol. 10, pp. 265 -278 (2019).
  • Pädiatrisches Krankenhaus Bambino Gesù Rom – Dr. G. Marini – ENT
    Marini et al. ”Pilot study to explore the prophylactic efficacy of oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngotonsillar episodes in pediatric patients.” Int J Gen Med., vol. 12, pp. 213-217 (2019).
  • Medizinische Universität Graz – Prof. Singer – Morbus Hirschsprung
    Singer et al. “Hirschsprung’s Associated Enterocolitis (HAEC) Personalized Treatment with Probiotics Based on Gene Sequencing Ana- lysis of the Fecal Microbiome,” Case Rep. Pediatr., pp. 1-6 (2018).
  • Medizinische Universität Graz – Prof. C. Högenauer – Irritable Bowel Syndrome
    Moser et al. “Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome.” Eur. J. Nutr., pp. 1-12 (2018).
  • Medizinische Universität Graz – Prof. E. Reininghaus – Bipolar disease
    Reininghaus et al. “The Impact of Probiotic Supplements on Cognitive Parameters in Euthymic Individuals with Bipolar Disorder: A Pilot Study.” Neuropsychobiology, pp. 1-8 (2018).
  • Medzinische Universität Innsbruck – Prof. D. Fuchs – Neurodegenerative diseases
    Leblhuber et al. “Probiotic Supplementation in Patients with Alzheimer’s Dementia – An Explorative Intervention Study.” Curr. Alzheimer Res., vol. 15, pp. 1106-1113 (2018).
  • Warwick Medical School – Dr. P. McTernant – Type 2 Diabetes
    Sabico et al. “Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial.” Clin Nutr., vol. 38, pp. 1561-1569 (2018).
  • Universität Graz – Prof. V. Schöpf – Neuropsychology / Neuroimaging
    Bagga et al. “Influence of 4-week multi-strain probiotic administration on resting-state functional connectivity in healthy volunteers.” Eur. J. Nutr., vol.58, pp. 1821-1827 (2018).
  • Pommersche Medizinische Universität Stettin – Dr. J. Suliburska – Hepatology
    Skrypnik et al. “Effect of probiotic supplementation on liver function and lipid status in rats.” Acta Sci. Pol. Technol. Aliment., vol. 17, pp. 185-192 (2018).
  • Lud. Max. Universität München – Prof. A. Straube – Migraines
    Straube et al. “Migräneprophylaxe mit einem Probiotikum.” MMW – Fortschritte der Medizin, vol. 160, pp. 16-21 (2018).
  • Medizinische Universität Posen – Dr. M. Szulinska – Metabolic Syndrome
    Szulinska et al. “Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial.” Nutrients, vol. 10, pp. 773 (2018).
  • Universität Graz – Prof. V. Schöpf – Neuropsychology / Neuroimaging
    Bagga et al. “Influence of 4-week multi-strain probiotic administration on resting-state functional connectivity in healthy volunteers.” Eur. J. Nutr., vol.58, pp. 1821-1827 (2018).
  • Pommersche Medizinische Universität Stettin – Dr. J. Suliburska – Hepatology
    Skrypnik et al. “Effect of probiotic supplementation on liver function and lipid status in rats.” Acta Sci. Pol. Technol. Aliment., vol. 17, pp. 185-192 (2018).
  • Medizinische Universität Posen – Dr. M. Szulinska – Metabolic Syndrome
    Szulinska et al. “Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial.” Nutrients, vol. 10, pp. 773 (2018).
  • Universität Graz – Prof. V. Schöpf – Neuropsychologie / Neuroimaging
    Bagga et al. “Probiotics drive gut microbiome triggering emotional brain signatures.” Gut Microbes, vol. 9, pp. 1-11, (2018).
  • Velleja Forschungsinstitut Mailand – Dr. F. Di Pierro – ENT
    Di Pierro et al. “Use of Streptococcus salivarius K12 to reduce the incidence pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects.” Minerva Pediatrica, vol. 70, pp. 240-245 (2018).
  • Universität Urbino – Dr. Baffone – Travel Medicine
    Campana et al., “Strain-specific probiotic properties of lactic acid bacteria against human intestinal pathogens invasion” Gut Pathog., vol. 9, pp. 12 (2017).
  • Warwick Medical School – Dr. P. McTernant – Type 2 Diabetes
    Sabico et al. “Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naive T2DM patients: a randomized clinical trial.” J Transl Med., vol. 15, pp. 249 (2017).
  • AKH Wien – Prof. L. Petricevic – Gynaecology
    Marschalek et al. “Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo- Controlled Double-Blinded Pilot Study.” Breast Care, vol. 12, pp. 335-339 (2017).
  • Medizinische Universität Innsbruck – Prof. D. Fuchs – neurodegenerative diseases
    Leblhuber et al. “On the role of intestinal microbiota in patients with cognitive decline.” J Pharm Pharmacol., vol. 5, pp. 648-653 (2017).
  • Medizinische Universität Innsbruck – Prof. D. Fuchs – Neurodegenerative diseases
    Leblhuber et al. “Die Bedeutung der Darm-Hirn-Achse bei Demenz.” Spectrum Psychiatrie vol. 3, pp. 38-41, (2017).
  • Universitätsklinikum Kiel – Prof. Schrezenmair – Gynaecology
    Laue et al. “Effect of Lactobacillus strains on bacterial vaginosis in women – a double-blind, randomised, controlled clinical pilot trial.” Benef. Microbes, vol. 9, pp. 35-50 (2017).
  • Bahçesehir Universität Istanbul – Ass. Prof. T. Gun – ENT
    Gun et al. “Clinical evaluation of the therapeutic use of oral probiotic Streptococcus salivarius K12 for recurrent pharyngitis and/or tonsillitis.” Indian Journal of Research, vol. 6, pp. 633-634 (2017).
  • Medizinische Universität Graz – Prof. V. Stadlbauer-Köllner – Hepatology
    Horvath et al. “Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis.” Aliment. Pharmacol. Ther., vol. 44, pp. 926-935 (2016).
  • Medizinische Universität Innsbruck – Prof. B. Prüller-Strasser – Performance enhancement / Sport
    Strasser et al. “Probiotic Supplements Beneficially Affect Tryptophan-Kynurenine Metabolism and Reduce the Incidence of Upper Respiratory Tract Infections in Trained Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial.” Nutrients, vol. 8, pp. 752 (2016).
  • Universitätsklinikum Kiew – Prof. Anoshina – Herpes infection during pregnancy
    Anoshina et al. “Role of microbiota in pregnant women with herpesvirus infection.” Perinatologiya Pediatriya, vol. 4, pp. 22-25 (2016).
  • Dr. Müller – Traveller’s Diarrhoea
    Müller H. “Probiotika zur Prophylaxe und Therapie der Reisediarrhö.” Flug u Reisemed., vol. 23(5) pp. 232-236 (2016).
  • Universität Genua – Dr. G. Gregori – ENT
    Gregori et al. “Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study.” Ther. Clin. Risk. Manag., vol. 19, pp. 87-92 (2016).
  • Universität Leiden – Prof. L. Colzato – Depression
    Steenbergen et al. “Randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood.” Brain. Behav. Immun., vol. 48, pp. 258-64 (2015).
  • Universität Wageningen – Dr. de Roos – Migraines
    de Roos et al. “The effects of the multispecies probiotic mixture on migraine: results of an open-label pilot study.” Benef. Microbes, vol. 6, pp. 641-646 (2015).
  • University College Roosevelt – Prof. G. Rijkers – Allergies
    Kim et al. “Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema.” Benef. Microbes, vol. 6, pp. 783-790 (2015).
  • Universität Innsbruck – Prof. Leblhuber – Dementia
    Leblhuber et al. “Elevated fecal calprotectin in patients with Alzheimer’s dementia indicates leaky gut.” J. Neural Transm., vol. 122, pp. 1319-1322 (2015).
  • LKH Feldbach – Doz. H. Hofmann – Paediatrics
    Hofmann H “Probiotikum gegen Verdauungsbeschwerden in der Schwangerschaft und Säuglingskoliken.” Gynäkologie aktiv, vol. 5, pp. 8-9 (2015).
  • AKH Wien – Prof. H. Kiss – Gynaecology
    Domig et al. “Strategies for the evaluation and selection of potential vaginal probiotics from human sources: an exemplary study.” Benef. Microbes, vol. 5, pp. 263-272 (2014).
  • AKH Wien – Dr. Ulrike Kaufmann – Transgender
    Kaufmann U et al. „Ability of an orally administered lactobacilli preparation to improve the quality of the neovaginal microflora in male to female transsexual women.“ European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 172, pp. 102-105 (2014).
  • Universität Wageningen – Prof. B. Schütz – Obesity
    van Hemert et al. “Clinical studies evaluating effects of probiotics on parameters of intestinal barrier function.” Advances in Microbiology, vol. 3, pp. 212-221 (2013).
  • Universität Linköping – Prof. Söderholm – Chronic inflammatory bowel diseases
    Persborn et al. “The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis.” Aliment. Pharmacol. Ther., vol. 38, pp. 772-783 (2013).
  • Universität Salzburg – Doz. M. Hell – CDAD
    Hell et al. “Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic.” Benef. Microbes, vol. 4, pp. 39-51 (2013).
  • Velleja Forschungsinstitut Mailand – Dr. F. Di Pierro –ENT
    Di Pierro et al. ”Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults.” Expert Opin Biol Ther., vol. 13, pp. 339-343 (2013).
  • Universität Graz – Doz. M. Lamprecht – Intestinal permeability and inflammation in sport
    Lamprecht et al. “Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial.” J Int Soc Sports Nutr., vol. 9, pp. 45 (2012).
  • Universität Graz – Doz. M. Lamprecht – Sports and nutritional medicine
    Lamprecht et al. “Exercise, intestinal barrier dysfunction and probiotic supplementation.” Med. Sport Sci., vol. 59, pp. 47-56 (2012).
  • Velleja Forschungsinstitut Mailand – Dr. F. Di Pierro – ENT
    Di Pierro et al. “Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.” Int. J. Gen. Med., vol. 5, pp. 991-997 (2012).
  • Universitätsklinik Utrecht – Prof. G. Rijkers – Allergies
    Niers et al. “The effects of selected probiotic strains on the development of eczema (the PandA study).” Allergy, vol. 64, pp. 1349-58 (2009).
  • Universitätsklinik Maastricht – Prof. R. Stockbrügger – Antibiotic-associated diarrhoea
    Koning et al. “The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin.” Am. J. Gastroenterol., vol. 103, pp. 178-189 (2008).
  • Universitätsklinik Utrecht – Prof. G. Rijkers – Allergies
    Niers et al. “Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells.” Clin. Exp. Immunol., vol. 149, pp. 344-352 (2007).
  • Universitätsklinik Utrecht – Prof. G. Rijkers – Allergies
    Niers et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin. Exp. Allergy, vol. 35, 1481-1489 (2005).
  • Johannes Gutenberg-Universität Mainz – Prof. K. Jung – Immune System
    H. Roll et al., „Beeinflussung von sekretorischen IgA-Defiziten bei Sportstudierenden durch Nahrungsergänzungsmittel“, EHK, vol 49 (8), pp 489-494, (2000).
  • Universität Freiburg – Prof. P. Berg – Immune System
    P. Berg et al., “The gastrointestinal system – an essential target organ of the athlete’s health and physical performance” Exerc Immunol Rev., (1999).

Studies with OMNi-BiOTiC® in publication:

  • University Hospital Rijeka (Dr Golcic): Chemotherapy-associated diarrhoea
  • University Hospital Graz (Prof. Stadlbauer Köllner): Stress Rest Study
  • University of Maribor (Prof. Fijan): Infections of the upper respiratory tract
  • UKE Hamburg (Prof. Stürmer): Wound healing in the diabetic foot
  • Medical University of Graz (Prof. Castellani): Neuroblastoma

A selection of ongoing research projects with OMNi-BiOTiC®:

  • Multicentre study in Germany (Prof. Labenz), antibiotic-associated diarrhoea

  • University Hospital Zurich (Prof. Scharl), Colorectal carcinoma

  • Medical University of Graz (Prof. Stadlbauer-Köllner), Dementia

  • University Hospital Rijeka (Prof. Hauser), Irritable Bowel Syndrome

  • AKH Vienna (Priv.-Doz. Aust), Ovarian carcinoma and prebiotics

  • Multicentre study in Austria (Prof. Gruber), Bacterial vaginosis

  • Multicentre study in Austria (Dr. Hammer), Prevention of ENT infections

  • Medical University of Graz (Prof. Stadlbauer-Köllner), Diarrhoea and Covid-19

  • Medical University Graz (Prof. Stadlbauer-Köllner) Probiotics use in PostCovid Syndrome

  • UKE Hamburg (Dr. Sinn), Colorectal carcinoma

  • LMU Munich (Prof. Liesz), Stroke

  • Medical University Graz (Dr. Mörkl), Depression

  • Medical University Graz (Prof. Voit-Augustin), Risk of infection in intensive care patients

  • Charité Berlin (Prof. Sehouli), Ovarian carcinoma

  • UKE Hamburg (Prof. Stürmer), Wound management of diabetic feet

  • University Hospital Minden (Dr. Sorleto), chronic pancreatitis

  • Medical University Graz (Prof. Stradner),Rheumatoid arthritis

  • Med Uni Vienna and Innsbruck (Prof. Karwautz), Anorexia

  • Medical University of Innsbruck (Dr. Kurz / Prof. Weiss), Chronic Fatigue

  • Fertility Centre Schenk (Dr. Krammer-Pojer / Dr. Schenk), Sperm quality

  • Medical University of Graz (Dr. Kollmann), Male Fertility

  • University of Veterinary Medicine Vienna (Prof. Burgener), Gastro-intestinal complaints in dogs

  • Medical University of Graz (Prof. Schemmer), Liver Transplantation

  • Medical University of Graz (Prof. Obermayer-Pietsch), PCOS

    If you have any questions about ongoing studies, please do not hesitate to contact us at Institut AllergoSan

Contact us for more information about our studies